Trial reportBMC ophthalmology2025
Effect of combined mature cataract surgery and intravitreal ranibizumab injection in eyes with pre-existing diabetic macular edema.
Trial report in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeThis study aimed to compare the functional and anatomical outcomes of combined cataract surgery and intravitreal ranibizumab injection in eyes with pre-existing diabetic macular edema (DME) and preoperatively obscured fundus due to advanced cataracts.
methodsAfter screening 350 eyes with diabetic cataracts and preoperatively obscured fundus, 39 eyes with intraoperatively confirmed DME were included in the final analysis. Eyes were randomly assigned to either the ranibizumab group (20 eyes) or the delayed treatment group (19 eyes). Best-corrected visual acuity (BCVA), total macular volume (TMV), and central subfield thickness (CST) were evaluated at 1, 4, and 12 weeks postoperatively. Intraoperative retinal examination techniques, including 25G optical fiber, wide-angle retinal photography, and intraoperative OCT, were used to enable real-time diagnosis and intervention.
resultsAt 12 weeks, the ranibizumab group showed a mean BCVA improvement of 34 letters, compared to 23 letters in the delayed group (P = 0.03). The mean change in CST was − 68 μm in the ranibizumab group and 33 μm in the delayed group (P = 0.05). Changes in TMV were similar between the two groups at 12 weeks.
conclusionIntravitreal ranibizumab injection during cataract surgery significantly improved visual acuity and reduced central subfield thickness at 12 weeks postoperatively in patients with pre-existing DME and preoperatively obscured fundus. This study highlights the importance of intraoperative retinal examination and timely anti-VEGF intervention in improving visual outcomes for this challenging patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.